KIDNEY TRANSPLANT
KIDNEY TRANSPLANT
To reduce rejections, doc gives free “rare drug”
SV KRISHNA CHAITANYA@Chennai
A city-based surgeon is using a “rare drug” developed in
Oxford University to reduce the acute rejection rate from 50 per cent to under
3 per cent.
Dr. Anil Vaidya, a leading Multi-Visceral transplant surgeon
working as a senior consultant with Apollo Hospitals, is the only surgeon in
the country who enjoys the luxury of importing Campath (Alemtuzumab) free of
cost and he in turn extends the benefit to his patients. The market price of
Campath is Rs 1 Lakh per mg.
Official statistics reveal out of 250 organ transplants,
primarily kidney and pancreas, done by Dr, Vaidya in last two years using
Campath, only four came back to get treated for rejection.
Dr. Vaidya told Express
that he obtained license from Drug General of India (DCGI) to bring Campath to
India. “I was part of the team that developed Campath in Oxford and later
pharmaceutical major Genzyme took over the patent rights. I was given the free
access to the drug under Campath Access Programme through which Indian patients
are getting benefited now.”
Though Campath is a licensed drug for treating Multiple Sclerosis (a condition where patient central nervous system gets slowly
disabled), Dr Vaidya convinced DCGI of its usage in organ transplants by
presenting data of 2,500 successful transplants done between Oxford and
Cambridge and obtained special license.
“Still every patient has to get registered and obtain
consent from DCGI. I submit details like audit report, patient numbers, severe
adverse effects of the drug to the authority annually.”
Dr. Vaidya uses 1/4th i.e., 15 mg compared to 60
mg used in west because Indians are more tolerant to foreign antigen.
Source: THE NEW SUNDAY EXPRESS, CHENNAI, SUNDAY, DECEMBER
23, 2018, LATE CITY EDITION
Comments